OncRef

Clinical Trial: NCT04032418

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Roswell Park Cancer Institute
Information Provided By:Roswell Park Cancer Institute
Last Update Posted:2026-09-21

Study Overview

Brief Summary

This phase II trial studies how well pembrolizumab given every 12 weeks works compared to every 3 weeks in treating patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab every 12 weeks may provide similar disease control with fewer treatments for patients with non-small cell lung cancer when compared to every 3 weeks. Demonstrating that 12 week dosing is as effective as 3 week dosing may also have a significant impact when considering the cost required for these medications.

Official Title

Randomized Phase II Study of Pembrolizumab 200mg every12 Weeks Versus Every 3 Weeks in NSCLC With Clinical Benefit to Pembrolizumab Monotherapy: Multicenter International Study

Conditions

Lung Non-Small Cell Carcinoma

Intervention / Treatment

  • Biological: Pembrolizumab

Other Study ID Numbers

  • i 82319
  • NCI-2019-04326
  • i 82319

Start Date (Actual)

2020-08-13

Primary Completion Date (Actual)

2025-03-14

Study Completion Date (Estimated)

2026-09-14

Enrollment (Actual)

9

Study Type

Interventional

Phase

Phase 2